Thus far, our data have suggested miR-146a prevents colonic inflammation and CRC development by suppressing both myeloid cell induction of IL-17-producing cells and responsiveness of IECs to IL-17 by targeting RIPK2 in myeloid cells and TRAF6 in IECs, respectively. The gene discussed is RIPK2; the disease is colorectal carcinoma.